Cart (0 Items)
Your cart is currently empty.
View Products
Accelerate your path to therapeutic antibodies with our portfolio of well-characterized, high-expression stable cell pools.
Whether you are advancing biosimilar programs with gold-standard antibodies or driving the development of novel biologics, our off-the-shelf monoclonal cell pools are optimized for high-speed monoclonal development and bulk production!
Ask for your fast monoclonal development or for a bulk quantity of therapeutic antibody below !
Each Stable cell pool is developed using our proprietary expression platform and quality-controlled
to ensure robust and consistent antibody production.
| Name of therapeutics (pool) | Target | Isotype | Yield | Therapeutic Area |
|---|---|---|---|---|
| Cetuximab | hEGFR | IgG1 | Between 5g/L and 10g/L | Oncology |
| Rituximab | MS4A1 | IgG1 | Between 5g/L and 10g/L | Immunotherapy |
| Ramucirumab | VEGFR-2 | IgG1Kappa | Between 5g/L and 10g/L | Oncology |
| Infliximab | TNF-alpha | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Adalimumab | TNF-alpha | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Nivolumab | PD-1 | IgG4 | Between 5g/L and 10g/L | Immunotherapy |
| Bevacizumab | VEGF | IgG1 | Between 5g/L and 10g/L | Oncology |
| Panitumumab | EGFR | IgG2-kappa | Between 5g/L and 10g/L | Oncology |
| Ustekinumab | Human IL-12 IL-23 | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Ranibizumab | VEGF | FabG1 | Between 5g/L and 10g/L | Oncology |
| Ipilimumab | CTLA-4 | IgG2-kappa | Between 5g/L and 10g/L | Immunotherapy |
| Natalizumab | ITGA4, CD49d | IgG4-kappa | Between 5g/L and 10g/L | Inflammation |
| Daclizumab | IL2RA | IgG1-kappa | Between 5g/L and 10g/L | Inflammation |
| Palivizumab | RSV | IgG1-kappa | Between 5g/L and 10g/L | Virology |
| Belimumab | TNFSF13B, CD257 | IgG1-lambda | Between 5g/L and 10g/L | Immunology |
| Denosumab | RANKL | IgG2Kappa | Between 5g/L and 10g/L | Developmental Biology |